Antibody-drug conjugates in precision oncology - PubMed

4 hours ago

Antibody-drug conjugates (ADCs) are a growing oncology therapy class, but successes are limited to few tumor types with frequent clinical setbacks.
ADC development faces challenges in patient selection, biomarker standardization, chemical design, and limited predictive preclinical models, often lacking validated biomarkers.
ADC activity involves more than target antigen expression; it includes tumor-intrinsic features and tumor microenvironment processes, supporting a conceptualization as tumor-ecosystem-targeting therapies.
The review connects ADC successes and failures to efficacy, resistance, and toxicity mechanisms, discussing biomarkers, combinations, next-gen platforms, and curative strategies for precision oncology.

Hasty Briefsbeta